Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model

This publication has 41 references indexed in Scilit:

• Sequential Treatment with Basic Fibroblast Growth Factor and Parathyroid Hormone Restores Lost Cancellous Bone Mass and Strength in the Proximal Tibia of Aged Ovariectomized Rats
  Journal of Bone and Mineral Research, 2001
• A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
  The American Journal of Medicine, 2000
• The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption
  Journal of Bone and Mineral Research, 2000
• Systemic Administration of Acidic Fibroblast Growth Factor (FGF-1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats
  Journal of Bone and Mineral Research, 1999
• In vivo, three-dimensional microscopy of trabecular bone
  Journal of Bone and Mineral Research, 1995
• The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats.
  Endocrinology, 1994
• Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.
  Endocrinology, 1993
• Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis
  Journal of Bone and Mineral Research, 1991
• In VivoStimulation of Bone Formation by Transforming Growth Factor-β
  Endocrinology, 1989
• THE MINIMUM EFFECTIVE DOSE OF ESTROGEN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS
  1984